{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:27:21Z","timestamp":1774625241046,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,8]]},"DOI":"10.7759\/cureus.37308","type":"journal-article","created":{"date-parts":[[2023,4,9]],"date-time":"2023-04-09T00:26:36Z","timestamp":1680999996000},"source":"Crossref","is-referenced-by-count":11,"title":["Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines"],"prefix":"10.7759","author":[{"given":"Parya","family":"Rahimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Behsheed","family":"Barootkoob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"ElHashash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arun","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19658","article-title":"Pediatric chemotherapy drugs associated with cardiotoxicity","volume":"13","author":"Hitawala G","year":"2021","unstructured":"Hitawala G, Jain E, Castellanos L, et al.. Pediatric chemotherapy drugs associated with cardiotoxicity. Cureus. 2021, 13:e19658. 10.7759\/cureus.19658","journal-title":"Cureus"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100015","article-title":"Predicting and preventing anthracycline-related cardiotoxicity","volume":"38","author":"Armenian S","year":"2018","unstructured":"Armenian S, Bhatia S. Predicting and preventing anthracycline-related cardiotoxicity. Am Soc Clin Oncol Educ Book. 2018, 38:3-12. 10.1200\/EDBK_100015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13120","article-title":"Prevention of cardiotoxicity among survivors of childhood cancer","volume":"83","author":"Hutchins KK","year":"2017","unstructured":"Hutchins KK, Siddeek H, Franco VI, Lipshultz SE. Prevention of cardiotoxicity among survivors of childhood cancer. Br J Clin Pharmacol. 2017, 83:455-65. 10.1111\/bcp.13120","journal-title":"Br J Clin Pharmacol"},{"key":"ref4","article-title":"Hypopituitarism Following Cranial Radiotherapy","author":"Pekic S","year":"2000","unstructured":"Pekic S, Miljic D, Popovic V. Hypopituitarism Following Cranial Radiotherapy. Endotext, South Dartmouth, MA; 2000."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5818612","article-title":"Genetic susceptibility and mechanisms underlying the pathogenesis of anthracycline-associated cardiotoxicity","volume":"2022","author":"Ding Y","year":"2022","unstructured":"Ding Y, Du K, Niu YJ, Wang Y, Xu X. Genetic susceptibility and mechanisms underlying the pathogenesis of anthracycline-associated cardiotoxicity. Oxid Med Cell Longev. 2022, 2022:5818612. 10.1155\/2022\/5818612","journal-title":"Oxid Med Cell Longev"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2021000268","article-title":"Minimizing cardiac toxicity in children with acute myeloid leukemia","volume":"2021","author":"Narayan HK","year":"2021","unstructured":"Narayan HK, Getz KD, Leger KJ. Minimizing cardiac toxicity in children with acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2021, 2021:368-75. 10.1182\/hematology.2021000268","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.07.096","article-title":"Echocardiographic long-term follow-up of adult survivors of pediatric cancer treated with Dexrazoxane-Anthracyclines association","volume":"299","author":"Filomena D","year":"2020","unstructured":"Filomena D, Versacci P, Cimino S, et al.. Echocardiographic long-term follow-up of adult survivors of pediatric cancer treated with Dexrazoxane-Anthracyclines association. Int J Cardiol. 2020, 299:271-5. 10.1016\/j.ijcard.2019.07.096","journal-title":"Int J Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-842","article-title":"Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms","volume":"14","author":"Deng S","year":"2014","unstructured":"Deng S, Yan T, Jendrny C, Nemecek A, Vincetic M, G\u00f6dtel-Armbrust U, Wojnowski L. Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms. BMC Cancer. 2014, 14:842. 10.1186\/1471-2407-14-842","journal-title":"BMC Cancer"},{"key":"ref9","article-title":"Dexrazoxane","author":"Eneh C","year":"2022","unstructured":"Eneh C, Lekkala MR. Dexrazoxane. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2022."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S47238","article-title":"Dexrazoxane for the treatment of chemotherapy-related side effects","volume":"6","author":"Langer SW","year":"2014","unstructured":"Langer SW. Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res. 2014, 6:357-63. 10.2147\/CMAR.S47238","journal-title":"Cancer Manag Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40959-019-0054-5","article-title":"Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors","volume":"5","author":"Bansal N","year":"2019","unstructured":"Bansal N, Adams MJ, Ganatra S, et al.. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology. 2019, 5:18. 10.1186\/s40959-019-0054-5","journal-title":"Cardiooncology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2018.889","article-title":"The cardioprotective effect of dexrazoxane (Cardioxane) is consistent with sequestration of poly(ADP-ribose) by self-assembly and not depletion of topoisomerase 2B","volume":"12","author":"McCormack K","year":"2018","unstructured":"McCormack K. The cardioprotective effect of dexrazoxane (Cardioxane) is consistent with sequestration of poly(ADP-ribose) by self-assembly and not depletion of topoisomerase 2B. Ecancermedicalscience. 2018, 12:889. 10.3332\/ecancer.2018.889","journal-title":"Ecancermedicalscience"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ppedcard.2014.09.007","article-title":"Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence","volume":"36","author":"Lipshultz SE","year":"2014","unstructured":"Lipshultz SE, Franco VI, Sallan SE, et al.. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence. Prog Pediatr Cardiol. 2014, 36:39-49. 10.1016\/j.ppedcard.2014.09.007","journal-title":"Prog Pediatr Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2017.457","article-title":"Risk factor analysis for secondary malignancy in dexrazoxane-treated pediatric cancer patients","volume":"51","author":"Kim H","year":"2019","unstructured":"Kim H, Kang HJ, Park KD, et al.. Risk factor analysis for secondary malignancy in dexrazoxane-treated pediatric cancer patients. Cancer Res Treat. 2019, 51:357-67. 10.4143\/crt.2017.457","journal-title":"Cancer Res Treat"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0210","article-title":"Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling","volume":"14","author":"Reichardt P","year":"2018","unstructured":"Reichardt P, Tabone MD, Mora J, Morland B, Jones RL. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncol. 2018, 14:2663-76. 10.2217\/fon-2018-0210","journal-title":"Future Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-019-09820-2","article-title":"Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens","volume":"24","author":"Cadeddu Dessalvi C","year":"2019","unstructured":"Cadeddu Dessalvi C, Pepe A, Penna C, et al.. Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens. Heart Fail Rev. 2019, 24:915-25. 10.1007\/s10741-019-09820-2","journal-title":"Heart Fail Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25043","article-title":"Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients","volume":"62","author":"Seif AE","year":"2015","unstructured":"Seif AE, Walker DM, Li Y, et al.. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients. Pediatr Blood Cancer. 2015, 62:704-9. 10.1002\/pbc.25043","journal-title":"Pediatr Blood Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.60.8851","article-title":"Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404","volume":"34","author":"Asselin BL","year":"2016","unstructured":"Asselin BL, Devidas M, Chen L, et al.. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. J Clin Oncol. 2016, 34:854-62. 10.1200\/JCO.2015.60.8851","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33974","article-title":"Late health outcomes after dexrazoxane treatment: a report from the Children's Oncology Group","volume":"128","author":"Chow EJ","year":"2022","unstructured":"Chow EJ, Aplenc R, Vrooman LM, et al.. Late health outcomes after dexrazoxane treatment: a report from the Children's Oncology Group. Cancer. 2022, 128:788-96. 10.1002\/cncr.33974","journal-title":"Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1311","article-title":"Pediatric anthracycline-induced cardiotoxicity: mechanisms, pharmacogenomics, and pluripotent stem-cell modeling","volume":"105","author":"Tripaydonis A","year":"2019","unstructured":"Tripaydonis A, Conyers R, Elliott DA. Pediatric anthracycline-induced cardiotoxicity: mechanisms, pharmacogenomics, and pluripotent stem-cell modeling. Clin Pharmacol Ther. 2019, 105:614-24. 10.1002\/cpt.1311","journal-title":"Clin Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvz031","article-title":"Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment","volume":"115","author":"Chow EJ","year":"2019","unstructured":"Chow EJ, Leger KJ, Bhatt NS, et al.. Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment. Cardiovasc Res. 2019, 115:922-34. 10.1093\/cvr\/cvz031","journal-title":"Cardiovasc Res"},{"key":"ref22","article-title":"Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity","volume":"8","author":"Zhang J","year":"2016","unstructured":"Zhang J, Cui X, Yan Y, Li M, Yang Y, Wang J, Zhang J. Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity. Am J Transl Res. 2016, 8:2862-75.","journal-title":"Am J Transl Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/147149-efficacy-of-dexrazoxane-in-cardiac-protection-in-pediatric-patients-treated-with-anthracyclines","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:56:19Z","timestamp":1707508579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/147149-efficacy-of-dexrazoxane-in-cardiac-protection-in-pediatric-patients-treated-with-anthracyclines"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,8]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.37308","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,8]]}}}